Acumen Pharmaceuticals(US:ABOS) Globenewswireยท2025-05-13 11:00Core Insights - Acumen Pharmaceuticals is focused on developing sabirnetug (ACU193), a novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment [2][12][14] - The company reported a net loss of $28.8 million for Q1 2025, an increase from $14.9 million in Q1 2024, primarily due to rising R&D expenses [9][21] - Acumen's cash, cash equivalents, and marketable securities totaled $197.9 million as of March 31, 2025, expected to support operations into early 2027 [6][8] Business Update - The Phase 2 study, ALTITUDE-AD, is fully enrolled with 542 participants, and topline results are anticipated in late 2026 [2][4][13] - The company presented at the International Conference on Alzheimer's and Parkinson's Diseases, showcasing the effectiveness of the plasma pTau217 assay in screening participants for ALTITUDE-AD [7] Financial Performance - R&D expenses for Q1 2025 were $25.3 million, up from $12.4 million in Q1 2024, reflecting increased clinical trial costs [8][21] - General and administrative expenses slightly decreased to $5.1 million in Q1 2025 from $5.3 million in Q1 2024 [8][21] - The total operating expenses for Q1 2025 were $30.4 million, compared to $17.8 million in Q1 2024 [8][21] Cash Flow and Balance Sheet - The company reported a net cash used in operating activities of $34.1 million for Q1 2025 [24] - Cash and cash equivalents at the end of Q1 2025 were $30.4 million, down from $47.2 million at the end of Q1 2024 [24]